Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | BAX | Q07812 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | STK39 | Q9UEW8 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RHEB | Q15382 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258619 | 0.89 | HSP90AA1 (0.57) | ESR2KMOHSP90AA1TSHRHSD17B10 | |
| SCHEMBL9623378 | 0.86 | ESR1 (0.58) | LTA4HNR1H2BAXESR2HSP90AA1 | |
| SCHEMBL8653830 | 0.85 | TSHR (0.52) | ESR2KMOHSP90AA1TSHRHSD17B10 | |
| SCHEMBL11056930 | 0.85 | HSP90AA1 (0.55) | LTA4HNR1H2BAXESR2KMO | |
| SCHEMBL1025535 | 0.84 | LTA4H (0.59) | LTA4HNR1H2BAXESR2KMO | |
| SCHEMBL9445013 | 0.83 | HSP90AA1 (0.68) | ESR2KMOHSP90AA1TSHRHSD17B10 | |
| SCHEMBL9592684 | 0.83 | KMO (0.45) | ESR2KMOHSP90AA1TSHRHSD17B10 | |
| SCHEMBL13048707 | 0.82 | HSP90AA1 (0.47) | HSP90AA1TSHRHSD17B10CA1CA2 | |
| SCHEMBL10704059 | 0.82 | CA1 (0.61) | HSP90AA1TSHRHSD17B10MAOBCA1 | |
| SCHEMBL8652143 | 0.82 | HSP90AA1 (0.47) | HSP90AA1TSHRHSD17B10CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115073469-B | Preparation and application of pyrrolopyrimidine compound as kinase inhibitor | 药雅科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-115073468-B | Preparation and application of imidazopyrazines BTK inhibitor | 药雅科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-115073468-A | Preparation and application of imidazopyrazine BTK inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073469-A | Preparation and application of pyrrolopyrimidine compound as kinase inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-6645997-B2 | Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1324995-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20020082292-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2002-06-27 | — | — | US | disclosed |
| WO-2002026729-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-5663453-A | CHEMICAL INTERMEDIATES FOR OVICIDES FOR INSECTS | CIBA-GEIBY CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0559612-B1 | Dioxolane derivatives as pesticides | CIBA GEIGY AG (CH) | 1996-08-14 | — | — | EP | disclosed |
| US-5151428-A | Insecticides and animal growth regulators | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-09-29 | — | — | US | disclosed |
| EP-0458361-A1 | Pyridine derivatives, their production processes and their compositions for the control of insect pests | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-11-27 | — | — | EP | disclosed |
| EP-0118377-B1 | PROCESS FOR THE PRODUCTION OF METACHLORINATED PHENOLS | RHONE-POULENC CHIMIE (FR) | 1988-03-09 | — | — | EP | disclosed |
| EP-0118377-A2 | Process for the production of metachlorinated phenols | RHONE-POULENC CHIMIE (FR) | 1984-09-12 | — | — | EP | disclosed |
| EP-0055196-B1 | PROCESS FOR THE SYNTHESIS OF METACHLOROPHENOLS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-04-18 | — | — | EP | disclosed |
| EP-0055198-B1 | PROCESS FOR THE SYNTHESIS OF METACHLOROPHENOLS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-04-04 | — | — | EP | disclosed |
| EP-0055197-B1 | PROCESS FOR THE SYNTHESIS OF METACHLOROPHENOLS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-04-04 | — | — | EP | disclosed |
| EP-0055196-A1 | Process for the synthesis of metachlorophenols | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-06-30 | — | — | EP | disclosed |
| EP-0055197-A1 | Process for the synthesis of metachlorophenols | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-06-30 | — | — | EP | disclosed |
| EP-0055198-A1 | Process for the synthesis of metachlorophenols | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082292-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | PPARD, PPARA, PPARG | LTA4H 2065/4885NR1H2 84/4885BAX 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.